SEC Company Response from Nuo Therapeutics, Inc. (AURX) (CIK 0001091596) (AURX) — Jul 1, 2013
Nuo Therapeutics, Inc. (AURX) (CIK 0001091596)
Date: July 1, 2013 · CIK: 0001091596 · Accession: 0001144204-13-037578
AI Filing Summary & Sentiment
File numbers found in text: 333-183703
Referenced dates: June 28, 2013
Letter
Division of Corporation Finance United States Securities and Exchange Commission Re: Cytomedix, Inc. Post-effective amendment to Form S-3 on Form S-1 Filed June 25, 2013 File No. 333-183703
Dear Mr. Mancuso:
On behalf of Cytomedix, Inc. (the “Company”) and in connection with the Post-effective Amendment to Form S-3 on Form S-1 filed by the Company with the Securities and Exchange Commission (the “Commission”) on June 25, 2013 (File No. 333-183703) (the “POS AM Filing”), we are writing in response to the comments of the staff of the Commission (the “Staff”) on the POS AM Filing as transmitted by a letter dated June 28, 2013 (the “Comment Letter”). For your convenience, we have restated the comments from the Comment Letter below, followed by the Company’s responses. For convenience, we have reprinted the Staff’s comments below in bold, with the corresponding response set forth immediately below the applicable comment. An amended filing to the POS AM Filing (the “Amended Filing”) reflecting changes in response to your comments is being filed today via the Commission’s EDGAR system.
Selling Security Holders, page 17
1. Regarding your response to prior comment 1, we note that you mention that no Cytomedix affiliates sold securities registered for sale on this registration statement after your notice. However, it is unclear when you provided the notice. Therefore, please tell us directly whether any Cytomedix affiliates sold any securities registered for sale on this registration statement since March 17, 2013.
Response:
No Cytomedix affiliates sold any securities registered for sale on this registration statement since March 17, 2013.
Exhibit 5.1
2. The third paragraph of this exhibit appears to omit counsel’s opinion on the shares mentioned in clause (ii) of the exhibit’s first paragraph. Please file an opinion that addresses all securities registered for sale on the registration statement.
Response:
A copy of the revised legal opinion correcting the inadvertent omission referenced in the comment above is filed today as an Exhibit 5.1 to the Amended Filing.
**************
Concurrently with this submission, the Company is also filing a separate letter, acknowledging that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We would appreciate the cooperation of the staff in working with us to address any further comments that the staff may have on the Company’s filings. We welcome the opportunity to speak with staff members directly in an effort to expedite the review process.
Please feel free to contact the undersigned in Washington DC at (202) 724-6846 should you required if you wish to discuss the Company’s revised submission.
Very truly yours,
/s/ F. Alec Orudjev
Show Raw Text
CORRESP
1
filename1.htm
901 K Street N.W., Suite 700
Washington, DC 20001
F. Alec Orudjev www.schiffhardin.com
aorudjev@schiffhardin.com
July 1, 2013
Mr. Russell Mancuso
Branch Chief
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Cytomedix, Inc.
Post-effective amendment to Form S-3 on Form S-1
Filed June 25, 2013
File No. 333-183703
Dear Mr. Mancuso:
On behalf of Cytomedix,
Inc. (the “Company”) and in connection with the Post-effective Amendment to Form S-3 on Form S-1 filed by the Company
with the Securities and Exchange Commission (the “Commission”) on June 25, 2013 (File No. 333-183703) (the “POS
AM Filing”), we are writing in response to the comments of the staff of the Commission (the “Staff”) on the POS
AM Filing as transmitted by a letter dated June 28, 2013 (the “Comment Letter”). For your convenience, we have restated
the comments from the Comment Letter below, followed by the Company’s responses. For convenience, we have reprinted the Staff’s
comments below in bold, with the corresponding response set forth immediately below the applicable comment. An amended filing to
the POS AM Filing (the “Amended Filing”) reflecting changes in response to your comments is being filed today via the
Commission’s EDGAR system.
Selling Security Holders, page 17
1. Regarding your
response to prior comment 1, we note that you mention that no Cytomedix affiliates sold securities registered for sale on this
registration statement after your notice. However, it is unclear when you provided the notice. Therefore, please tell us directly
whether any Cytomedix affiliates sold any securities registered for sale on this registration statement since March 17, 2013.
Response:
No Cytomedix affiliates
sold any securities registered for sale on this registration statement since March 17, 2013.
Exhibit 5.1
2. The third paragraph
of this exhibit appears to omit counsel’s opinion on the shares mentioned in clause (ii) of the exhibit’s first paragraph.
Please file an opinion that addresses all securities registered for sale on the registration statement.
Response:
A copy of the revised
legal opinion correcting the inadvertent omission referenced in the comment above is filed today as an Exhibit 5.1 to the Amended
Filing.
**************
Concurrently with this
submission, the Company is also filing a separate letter, acknowledging that:
· should the Commission or the staff, acting
pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with
respect to the filing;
· the action of the Commission or the staff,
acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility
for the adequacy and accuracy of the disclosure in the filing; and
· the company may not assert staff comments
and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.
We would appreciate
the cooperation of the staff in working with us to address any further comments that the staff may have on the Company’s
filings. We welcome the opportunity to speak with staff members directly in an effort to expedite the review process.
Please feel free to
contact the undersigned in Washington DC at (202) 724-6846 should you required if you wish to discuss the Company’s revised
submission.
Very truly yours,
/s/ F. Alec Orudjev
F. Alec Orudjev
Cc: Martin P. Rosendale, CEO
Steven A. Shallcross,
CFO